-
1
-
-
84928580276
-
Studies on prostate cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate
-
Huggins C, Hodges CV: Studies on prostate cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293, 1941.
-
(1941)
Cancer Res
, vol.1
, pp. 293
-
-
Huggins, C.1
Hodges, C.V.2
-
2
-
-
0014088849
-
Treatment and survival of patients with cancer of the prostate
-
Veterans Administration Cooperative Urological Research Group
-
Veterans Administration Cooperative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124:1011, 1967.
-
(1967)
Surg Gynecol Obstet
, vol.124
, pp. 1011
-
-
-
3
-
-
0023726635
-
Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group Studies
-
Byar DP, Corle DK: Hormone therapy for prostate cancer: Results of the Veterans Administration Cooperative Urological Research Group studies. Natl Cancer Inst Monogr 7:165, 1988. (Pubitemid 18225389)
-
(1988)
NCI Monographs
, Issue.7
, pp. 165-170
-
-
Byar, D.P.1
Corle, D.K.2
-
4
-
-
0029090784
-
A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma
-
Casodex Study Group
-
Kalsary AV, Tyrrell CJ, Beacock C, et al: A randomised comparison of monotherapy with Casodex 50 mg daily and castration in the treatment of metastatic prostate carcinoma. Casodex Study Group. Eur Urol 28:215-222, 1995.
-
(1995)
Eur Urol
, vol.28
, pp. 215-222
-
-
Kalsary, A.V.1
Tyrrell, C.J.2
Beacock, C.3
-
5
-
-
0029882360
-
Randomised study of Casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer
-
The Scandinavian Casodex Cooperative Group
-
Iversen P, Tveter K, Varenhorst E: Randomised study of Casodex 50 mg monotherapy vs orchidectomy in the treatment of metastatic prostate cancer. The Scandinavian Casodex Cooperative Group. Scand J Urol Nephrol 30:93-98, 1996.
-
(1996)
Scand J Urol Nephrol
, vol.30
, pp. 93-98
-
-
Iversen, P.1
Tveter, K.2
Varenhorst, E.3
-
6
-
-
0035321536
-
Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: A systematic review
-
Schmitt B, Wilt TJ, Schellhammer PF, et al: Combined androgen blockade with non-steroidal antiandrogens for advanced prostate cancer: A systematic review. Urology 57:727-732, 2001.
-
(2001)
Urology
, vol.57
, pp. 727-732
-
-
Schmitt, B.1
Wilt, T.J.2
Schellhammer, P.F.3
-
7
-
-
58149170709
-
Twenty-five year evolution of medical hormonal therapy for prostate cancer
-
Moul JW: Twenty-five year evolution of medical hormonal therapy for prostate cancer. BJU Int 103:145-146, 2009.
-
(2009)
BJU Int
, vol.103
, pp. 145-146
-
-
Moul, J.W.1
-
8
-
-
0023226588
-
Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist
-
Labrie F, Dupont A, Belanger A, et al: Flutamide eliminates the risk of disease flare in prostatic cancer patients treated with a luteinizing hormone-releasing hormone agonist. J Urol 138:804-806, 1987. (Pubitemid 17150766)
-
(1987)
Journal of Urology
, vol.138
, Issue.4
, pp. 804-806
-
-
Labrie, F.1
Dupont, A.2
Belanger, A.3
Lachance, R.4
-
9
-
-
0036088023
-
Hormonal therapy for prostate cancer: Past, present and future
-
el-Rayes BF, Hussain MH: Hormonal therapy for prostate cancer: Past, present and future. Expert Rev Anticancer Ther 2:37-47, 2002.
-
(2002)
Expert Rev Anticancer Ther
, vol.2
, pp. 37-47
-
-
El-Rayes, B.F.1
Hussain, M.H.2
-
10
-
-
0037299787
-
A phase 3, multicenter, open-label randomized study of abarelix versus leuprolide acetate in men with prostate cancer
-
MacLeod DG, Zinner N, Tomera K, et al: A phase 3, multicenter, open-label randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 61(suppl 1):3-7, 2003.
-
(2003)
Urology
, vol.61
, Issue.SUPPL. 1
, pp. 3-7
-
-
MacLeod, D.G.1
Zinner, N.2
Tomera, K.3
-
11
-
-
0036128522
-
A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer
-
Trachtenberg J, Gittleman M, Steidle C, et al: A phase 3, multicenter, open-label randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol 167:1670-1674, 2002. (Pubitemid 34240698)
-
(2002)
Journal of Urology
, vol.167
, Issue.4 I
, pp. 1670-1674
-
-
Trachtenberg, J.1
Gittleman, M.2
Steidle, C.3
Barzell, W.4
Friedel, W.5
Pessis, D.6
Fotheringham, N.7
Campion, M.8
Garnick, M.B.9
-
12
-
-
84888534748
-
-
note
-
Lupron Depot 7.5 mg (package insert). Lake Forest, Ill; TAP Pharmaceuticals Inc; 2007.
-
-
-
-
13
-
-
1242341916
-
Targeting FSH in androgen-independent prostate cancer: Abarelix for prostate cancer progressing after orchiectomy
-
DOI 10.1016/j.urology.2003.09.045
-
Beer TM, Garzotto M, Eilers KM, et al: Targeting FSH in androgen-independent prostate cancer: Abarelix for prostate cancer progressing after orchiectomy. Urology 63:342-347, 2004. (Pubitemid 38234432)
-
(2004)
Urology
, vol.63
, Issue.2
, pp. 342-347
-
-
Beer, T.M.1
Garzotto, M.2
Eilers, K.M.3
Lemmon, D.4
Wersinger, E.M.5
-
14
-
-
44049099624
-
Gonadotropin-releasing hormone antagonist in the management of prostate cancer
-
Debruyne FM: Gonadotropin-releasing hormone antagonist in the management of prostate cancer. Rev Urol 6(suppl 7):S25-S32, 2004.
-
(2004)
Rev Urol
, vol.6
, Issue.SUPPL. 7
-
-
Debruyne, F.M.1
-
15
-
-
0035046991
-
The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
-
Tomera K, Gleason D, Gittelman M, et al: The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 165:1585-1589, 2001. (Pubitemid 32410246)
-
(2001)
Journal of Urology
, vol.165
, Issue.5 I
, pp. 1585-1589
-
-
Tomera, K.1
Gleason, D.2
Gittelman, M.3
Moseley, W.4
Zinner, N.5
Murdoch, M.6
Menon, M.7
Campion, M.8
Garnick, M.B.9
-
18
-
-
0035944837
-
Gonadotropin-releasing-hormone-receptor antagonists
-
Huirne JAF, Lambalk CB: Gonadotropin-releasing-hormone-receptor antagonists. Lancet 358:1793-1803, 2001.
-
(2001)
Lancet
, vol.358
, pp. 1793-1803
-
-
Huirne, J.A.F.1
Lambalk, C.B.2
-
19
-
-
50849110501
-
Degarelix: A novel gonadotropin-releasing hormone (GnRH) blocker - Results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer
-
Van Poppel H, Tombal B, de la Rosette JM, et al: Degarelix: A novel gonadotropin-releasing hormone (GnRH) blocker - results from a one-year, multicentre, randomised, phase 2 dose-finding study in the treatment of prostate cancer. Eur Urol 54:805-815, 2008.
-
(2008)
Eur Urol
, vol.54
, pp. 805-815
-
-
Van Poppel, H.1
Tombal, B.2
De La Rosette, J.M.3
-
20
-
-
53249121469
-
A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America
-
Gittelman M, Pommerville PJ, Persson BE, et al: A 1-year, open-label, randomized phase II dose-finding study of degarelix, a novel gonadotropin-releasing hormone (GnRH) receptor blocker, in the treatment of prostate cancer in North America. J Urol 180:1986-1992, 2008.
-
(2008)
J Urol
, vol.180
, pp. 1986-1992
-
-
Gittelman, M.1
Pommerville, P.J.2
Persson, B.E.3
-
21
-
-
56649116179
-
The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer
-
Klotz L, Boccon-Gibod L, Shore ND, et al: The efficacy and safety of degarelix: A 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 102:1531-1538, 2008.
-
(2008)
BJU Int
, vol.102
, pp. 1531-1538
-
-
Klotz, L.1
Boccon-Gibod, L.2
Shore, N.D.3
-
22
-
-
84888485838
-
Degarelix compared to leuprolide depot 7.5 mg in a 12-month randomised, open-label, parallel-group phase III study in prostate cancer patients
-
(abstract 537) Presented at the
-
Boccon-Gibod L, Klotz L, Schröder H, et al: Degarelix compared to leuprolide depot 7.5 mg in a 12-month randomised, open-label, parallel-group phase III study in prostate cancer patients (abstract 537). Presented at the 23rd Annual EAU Congress, Milan, Italy, 2008.
-
23rd Annual EAU Congress, Milan, Italy, 2008
-
-
Boccon-Gibod, L.1
Klotz, L.2
Schröder, H.3
-
24
-
-
33646036678
-
FSH directly regulates bone mass
-
Sun L, Peng YZ, Sharrow AC, et al: FSH directly regulates bone mass. Cell 125:247-260, 2006.
-
(2006)
Cell
, vol.125
, pp. 247-260
-
-
Sun, L.1
Peng, Y.Z.2
Sharrow, A.C.3
-
25
-
-
84870960298
-
-
Available at Accessed March 20, 2009
-
American Cancer Society: How many men get prostate cancer? Available at http://www.cancer.org/. Accessed March 20, 2009.
-
How Many Men Get Prostate Cancer?
-
-
|